Hybrid closed loop technology was associated with superior efficacy and safety outcomes relative to standard insulin therapy in T1D.

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone shots for people with a rare genetic form of lipodystrophy that leaves patients ...

A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.

A groundbreaking stem cell therapy offers new hope for type 1 diabetes, with early results showing potential for insulin ...

Many drugs, including insulin, essentially became free. But the American Rescue Plan made a major change that hit drug companies with even larger penalties for raising prices. In January 2024 ...

A University of Massachusetts Amherst-Ernest Pharmaceuticals team of scientists has made "exciting," patient-friendly advances in developing a non-toxic bacterial therapy, BacID, to deliver cancer ...

While this option may be less expensive and seems convenient, it’s best to consult a doctor about dosage if you use it, says Joshua J. Neumiller, CDCES, PharmD, the president elect of ...

"Multiple innovations have improved automated insulin delivery systems, which constitute the most advanced therapy for type 1 diabetes. For that reason, the placebo intervention, which consisted ...